Sep 20, 2022

UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration

Posted by in categories: biotech/medical, life extension

Enrollment of 51 patients exceeds target by ~10% due to high interest in the study

16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the ENVISION study, its Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degeneration (AMD). This is an active comparator study, examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

Leave a reply